Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

189.28 -1.47 (-0.77%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
81 82 Next >
3 Dividend Stocks That Can Power Your Portfolio for Decades
From healthcare to home repair to tech, these stocks can help diversify your holdings. 
Via The Motley Fool
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie. 
Via InvestorPlace
Pfizer Posted a Steep Loss. Is It Time to Sell?
A $5.6 billion inventory write-down isn't what investors wanted to see, but this company is made of many moving pieces. 
Via The Motley Fool
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
Via Investor Brand Network
AbbVie Unusual Options Activity
Via Benzinga
2 No-Brainer Dividend Stocks to Buy This Week
These two top-income stocks are too cheap to ignore. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors
AbbVie has a head start, but that might not be enough to save its top line. 
Via The Motley Fool
Amgen Lifts Annual Outlook After Q3 Performance, But Stock Still Falls - Here's Why
Amgen Inc (NASDAQ: AMGN) reported Q3 FY23 sales of $6.90 billion, slightly missin 
Via Benzinga
J&J stock down as business unit mulls talc-related bankruptcy
Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements. 
Via MarketBeat
Topics Bankruptcy Lawsuit
Is AbbVie Still a Good Dividend Stock to Buy?
The decline in sales of Humira, AbbVie's top seller, is enough to make anyone nervous. 
Via The Motley Fool
Why AbbVie Stock Fell Today
AbbVie stock fell despite beating third-quarter expectations and raising its full-year outlook. Here's what investors need to know. 
Via The Motley Fool
Earnings Outlook For AbbVie
Via Benzinga
Why AbbVie Stock Was a Winner on Monday
One analyst tracking the pharmaceutical major upgraded his recommendation. 
Via The Motley Fool
AbbVie Analysts Increase Their Forecasts After Upbeat Earnings
AbbVie Inc (NYSE: ABBV) reported better-than-expected earnings for its third quarter and raised its profit outlook on Friday. 
Via Benzinga
AbbVie To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
AbbVie Inc. Dividend Increase
AbbVie Inc. recently announced its next dividend of $1.55 per share, a 4.73% increase over the company's previous payout of $1.48. 
Via Talk Markets
AbbVie (ABBV) Q3 2023 Earnings Call Transcript
ABBV earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
FDA Gives Nod To Eli Lilly's First Treatment For Type Of Inflammatory Bowel Disease, To Compete With JNJ, Pfizer, AbbVie
The FDA approved Eli Lilly And Co's  
Via Benzinga
AbbVie Raises Annual Profit Outlook As Newer Immunology Drugs Help Cushion Struggling Humira Sales
AbbVie Inc (NYSE: ABBV) has reported Q3 adjusted EPS of $2.95, down 19.4% Y/Y, beating the consensus of $2.88. 
Via Benzinga
High-yield, deep-value AbbVie fell off the patent cliff and lived
AbbVie's deep value and high yield attract income investors, and the patent cliff worry lessens daily. 
Via MarketBeat
Topics Intellectual Property
AbbVie Stock Slips As Humira Struggles Continue, But Drugmaker Raises Outlook
Humira sales continued to decline amid a battle with new biosimilars in the U.S. 
Via Investor's Business Daily
Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
The market has punished them, but don't overlook these stocks. 
Via The Motley Fool
Earnings Scheduled For October 27, 2023
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is projected to report quarterly earnings at $2.26 per share on revenue of $12.56 billion. 
Via Benzinga
The 7 Best Forever Stocks to Buy for October 2023
These forever stocks have held up incredibly well despite the economic troubles offering healthy upside compared to its peers. 
Via InvestorPlace
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at... 
Via Talk Markets
Topics Economy
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets
In the week ahead, earnings season moves into full swing with reports from companies like Microsoft, Alphabet, Meta Platforms and Amazon. 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.